Senior researcher, Dr. Padmanee Sharma, said the findings “are significant and clinically meaningful to patients and health care professionals alike.”
The research team compared the effects of Opdivo with another common drug called Afinitor. 800 people with advanced kidney cancer received the treatment. Shrinkage of tumors was seen in all patients.
What made Opdivo stand apart from Afinitor was that those who used Opdivo had better outcomes. Survival rates rose from 19.6 months – for those on Afinitor – to 25 months. Tumor shrinkage was also greater in those on Opdivo than those on Afinitor. Lastly, although both groups saw side effects, more side effects were associated with Afinitor (37 percent) then Opdivo (19 percent).
Drug-related deaths were not seen in the Opdivo group but two occurred in the Afinitor group.
Dr. William Oh from Mount Sinai hospital in New York said, “Treatment options for metastatic kidney cancer remain inadequate for most patients. Available drugs have limited activity or excess toxicity and new therapies are urgently needed.”
Opdivo has also been shown to work against other cancers, such as melanoma and lung malignancies.
Sharma concluded, “Although we cannot speculate at this time on when nivolumab [Opdivo] might enter the clinic, we hope that this study will quickly lead to approval of nivolumab as a standard of care therapy for these patients.”
The findings were published in the New England Journal of Medicine.